NOVEL USE OF SUBSTITUTED AMINOMETHYLCHROMANS Russian patent published in 2008 - IPC C07D405/12 A61K31/4433 A61P25/14 A61P25/16 

Abstract RU 2322443 C2

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to drugs and concerns using (2R,4R)-2-({[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-amino}-methyl)-chroman-4-ol or its pharmaceutically acceptable salts or solvates used for production of a drug for treatment of catalepsy. Also, invention proposes a pharmaceutical composition for treatment of catalepsy that comprises (2R,4R)-2-({[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-amino}-methyl)-chroman-4-ol as an active component taken in the pharmaceutically effective amount in combination with one or some pharmaceutically acceptable excipients.

EFFECT: valuable medicinal properties of compound and pharmaceutical composition.

3 cl, 15 ex

Similar patents RU2322443C2

Title Year Author Number
NOVEL USING 2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMAN AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS 2002
  • Bartoshik Gerd
  • Russ Germann
  • Zejfrid Kristof
  • Veber Frank
RU2297833C2
METHODS FOR TREATMENT OF BEHAVIOR CHANGES 2018
  • Maes, Tamara
  • Rotllant Pozo, David
  • Grinan Ferre, Christian
  • Pallas Lliberia, Merce
  • Nadal Alemany, Roser
  • Almario Garcia, Antonio
RU2799049C2
CHROMON OXIME NEW DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS 2015
  • Charvin, Delphine
  • Manteau, Baptiste
  • Pomel, Vincent
  • Conquet, Francois
RU2672569C2
3R,4S 3-[4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDIN-1- YL)CHROHAN-4,7-DIOL, OPTICAL ISOMERS THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON, AND METHOD OF MEDICAL TREATMENT 1994
  • Todd V.Batler
  • Bertrand L.Chenard
RU2126404C1
SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO [3_2_0] HEPT-3-EN-6-ONE 2016
  • Ford Rhonan Lee
  • Meghani Premji
RU2734475C2
SYNERGETIC TREATMENT OF PARKINSONISM 1995
  • Bertran L. Chenard
  • Frank S. Menniti
RU2176145C2
NOVEL USING SUBSTITUTED AMINOMETHYLCHROMANS IN TREATMENT OF MOTION DISORDER OR UNDESIRABLE EFFECT CAUSED BY AGENTS THAT ARE ADMINISTRATED IN TREATMENT OF EXTRAPYRAMID MOTION DISORDER 2002
  • Bartoshik Gerd
  • Russ Germann
  • Zejfrid Kristof
  • Bettkher Khenning
  • Bokel' Khajnts-Germann
  • Shmid-Grossmann Ushi
RU2320336C2
NOVEL SALT FORM OF DOPAMINE AGONIST 2006
  • Grin Stjuart Piter
  • Ladzari Oliv'E Alen
  • Miller Dunkan Charl'Z
  • Saling Fabris Genri
RU2393153C2
7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZIOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(PROPYNYL)-7H-PYRAZOLO-[4, 3-e]-[1, 2, 4]-TRIAZOLO-[1, 5-c]PYRIMIDINE-5-AMINE 2006
  • Bojl Krejg D.
  • Chakkalamannil Samjuehl'
  • Shakh Unmesh G.
  • Lakhovich Zhan Eh.
RU2417997C2
COMBINED THERAPY BASED ON CD20 ANTIBODY COMBINED WITH BCL-2 INHIBITOR AND MDM2 INHIBITOR 2016
  • Klyajn Kristian
  • Kherting Frank
  • Dangl Markus
RU2727196C2

RU 2 322 443 C2

Authors

Khenning Bettkher

Ral'F Defant

Gerd Bartoshik

Germann Russ

Frank Veber

Kristof Zejfrid

Dates

2008-04-20Published

2002-08-12Filed